Human leukocyte antigen B*0702 is protective against ocular Stevens-Johnson syndrome/toxic epidermal necrolysis in the UK population.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Genetic Predisposition to Disease*; Eye Diseases/*genetics ; HLA-B7 Antigen/*genetics ; Stevens-Johnson Syndrome/*genetics; Adolescent ; Adult ; Aged ; Alleles ; Child ; Child, Preschool ; Eye Diseases/epidemiology ; Eye Diseases/immunology ; Female ; HLA-B7 Antigen/immunology ; Humans ; Incidence ; Male ; Middle Aged ; Protective Factors ; Stevens-Johnson Syndrome/epidemiology ; Stevens-Johnson Syndrome/immunology ; United Kingdom/epidemiology ; Young Adult

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN) are part of a disease continuum of vesiculobullous mucocutaneous reactions affecting the skin and mucous membranes including the ocular surface. Manifestations of disease range from mild dry eye to progressive conjunctival cicatrisation, limbal epithelial stem cell failure and corneal blindness. In Far Eastern and South East Asian populations where SJS/TEN is prevalent, numerous human leukocyte antigen (HLA) gene variants at the A, B and C loci have been identified as risk factors for developing SJS/TEN with severe ocular complications (SOC). By contrast, the incidence of SJS/TEN with SOC in European countries is relatively low. To date, ocular SJS/TEN risk altering alleles have not been widely investigated in European populations. In this study, we analysed the association of HLA -A, -B and -C alleles with SJS/TEN in 33 patients residing in the UK with age matched controls. The data showed statistically significant novel negative allele association with HLA-B*0702 and a trend with HLA-C*0702 in the patient group, indicating these alleles are protective. Further characterisation of protective and risk alleles in other ethnic groups is required to fully elucidate the putative role of these alleles in the susceptibility of SJS/TEN with or without severe ocular complications in patients in the UK.

Eye (Lond). 2012 Sep;26(9):1199-208. (PMID: 22722485)
Ophthalmology. 1996 Sep;103(9):1406-9. (PMID: 8841298)
Epilepsia. 2015 Oct;56(10):e161-7. (PMID: 26282450)
Br J Ophthalmol. 2018 Sep;102(9):1303-1307. (PMID: 29706602)
Cornea. 2016 Feb;35(2):199-204. (PMID: 26655481)
Arch Intern Med. 1992 Jul;152(7):1513-6. (PMID: 1627031)
Sci Rep. 2014 Apr 30;4:4862. (PMID: 24781922)
Am J Clin Dermatol. 2015 Dec;16(6):475-93. (PMID: 26481651)
Br J Dermatol. 2016 Jun;174(6):1194-227. (PMID: 27317286)
PLoS One. 2016 Nov 11;11(11):e0165933. (PMID: 27835661)
Epilepsia. 2010 Feb;51(2):297-300. (PMID: 19694795)
J Invest Dermatol. 2017 Jun;137(6):1240-1247. (PMID: 28202399)
Br J Ophthalmol. 2007 Aug;91(8):1048-53. (PMID: 17314145)
Epilepsia. 2010 Dec;51(12):2461-5. (PMID: 21204807)
Sci Rep. 2014 Aug 07;4:5981. (PMID: 25099678)
Allergy. 2007 May;62(5):527-31. (PMID: 17313402)
Drug Metabol Drug Interact. 2014;29(2):67-79. (PMID: 24406279)
Hum Genome Var. 2019 Oct 28;6:50. (PMID: 31666976)
Ophthalmology. 2009 Apr;116(4):685-90. (PMID: 19243825)
Nat Med. 2008 Dec;14(12):1343-50. (PMID: 19029983)
Invest Ophthalmol Vis Sci. 2018 Nov 1;59(14):DES183-DES191. (PMID: 30481825)
J Invest Dermatol. 2016 Jul;136(7):1387-1397. (PMID: 27039263)
Br J Ophthalmol. 2019 Apr;103(4):573-576. (PMID: 30705045)
Pharmacogenomics. 2006 Sep;7(6):813-8. (PMID: 16981842)
Front Immunol. 2017 Dec 11;8:1776. (PMID: 29312307)
Pediatrics. 2007 Apr;119(4):e1002-5. (PMID: 17353300)
Am J Ophthalmol. 2007 Feb;143(2):367-8. (PMID: 17258541)
Sci Rep. 2017 Nov 21;7(1):15960. (PMID: 29162886)
Am J Ophthalmol. 2015 Aug;160(2):228-237.e2. (PMID: 25979679)
Pharmacogenomics. 2012 Aug;13(11):1285-306. (PMID: 22920398)
Science. 1998 Oct 16;282(5388):490-3. (PMID: 9774279)
Ophthalmology. 2007 Jul;114(7):1294-302. (PMID: 17475335)
Sci Rep. 2019 Nov 7;9(1):16240. (PMID: 31700100)
JAMA Ophthalmol. 2017 Apr 1;135(4):355-360. (PMID: 28278336)
Proc Natl Acad Sci U S A. 2013 May 28;110(22):E2046-53. (PMID: 23580623)
Invest Ophthalmol Vis Sci. 2008 May;49(5):1809-13. (PMID: 18263811)
Arch Dermatol. 2009 Feb;145(2):157-62. (PMID: 19221260)
Mol Vis. 2008 Mar 17;14:550-5. (PMID: 18385790)

0 (HLA-B*07:02 antigen)
0 (HLA-B7 Antigen)

Date Created: 20210204 Date Completed: 20211115 Latest Revision: 20211115

20250114

PMC7859395

10.1038/s41598-021-82400-3

33536518